Specifically, SGLT2 inhibitors were associated with a reduced risk of AF, when HF was not used as an inclusion criterion or when patients with HFrEF were included, but not in patients with HFmrEF or HFpEF (P-value for group difference = 0.01). The gene discussed is SLC5A2; the disease is hydrops fetalis.